LEADER 03419nam  22006851  450 
001 9910791912903321
005 20120628124337.0
010   $a1-84731-909-2
010   $a1-4742-0077-X
010   $a1-283-53952-7
010   $a9786613851970
010   $a1-84731-908-4
024 7 $a10.5040/9781474200776
035   $a(CKB)2560000000090539
035   $a(EBL)990457
035   $a(OCoLC)805517578
035   $a(SSID)ssj0000701503
035   $a(PQKBManifestationID)12261547
035   $a(PQKBTitleCode)TC0000701503
035   $a(PQKBWorkID)10676040
035   $a(PQKB)11509513
035   $a(MiAaPQ)EBC1772924
035   $a(MiAaPQ)EBC990457
035   $a(Au-PeEL)EBL1772924
035   $a(CaPaEBR)ebr10589790
035   $a(CaONFJC)MIL385197
035   $a(OCoLC)893332401
035   $a(OCoLC)809536917
035   $a(UtOrBLW)bpp09259369
035   $a(MiAaPQ)EBC6164402
035   $a(Au-PeEL)EBL990457
035   $a(EXLCZ)992560000000090539
100   $a20150827d2012      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aLaw and the regulation of medicines /$fEmily Jackson
205   $a1st ed.
210  1$aOxford ;$aPortland, Ore. :$cHart Publishing,$d2012.
215   $a1 online resource (308 p.)
300   $aDescription based upon print version of record.
311   $a1-84946-179-1 
320   $aIncludes bibliographical references (pages 267-292).
327   $aWhat are medicines and why are they special? -- Clinical trials -- Licensing -- Pharmacovigilance and liability for dangerous drugs -- Marketing -- Funding and access to medicines in the UK -- Funding and access to medicines : a global problem -- The future of medicines I : pharmacogenetics -- The future of medicines II : enhancement.
330   $a"The principal purpose of this book is to tell the story of a medicine's journey through the regulatory system in the UK, from defining what counts as a medicine, through clinical trials, licensing, pharmacovigilance, marketing and funding. The question of global access to medicines is addressed because of its political importance, and because it offers a particularly stark illustration of the consequences of classifying medicines as a private rather than a public good. Two further specific challenges to the future of medicine's regulation are examined separately: first, pharmacogenetics, or the genetic targeting of medicines to subgroups of patients, and second, the possibility of using medicines to enhance well-being or performance, rather than treat disease. Throughout, the emphasis is on the role of regulation in shaping and influencing the operation of the medicines industry, an issue that is of central importance to the promotion of public health and the fair and equitable distribution of healthcare resources."--Bloomsbury Publishing.
606   $aDrugs$xLaw and legislation$zGreat Britain
606   $aPharmacy$xLaw and legislation$zGreat Britain
606   $2Medical & healthcare law
615  0$aDrugs$xLaw and legislation
615  0$aPharmacy$xLaw and legislation
676   $a344.410416
700   $aJackson$b Emily$f1966-$01496592
801  0$bUtOrBLW
801  1$bUtOrBLW
906   $aBOOK
912   $a9910791912903321
996   $aLaw and the regulation of medicines$93798642
997   $aUNINA